MedTrace Logo

The Effect of GnRH Agonist Administered in the Luteal Phase on ART Cycle Outcomes

NCT02114645 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2014-04-15

No results posted yet for this study

Summary

This prospective clinical trial evaluates the effect of a two dose GnRH agonist administered in the luteal phase on the outcome of ART cycles stimulated with the long GnRH agonist and GnRH antagonist protocol.

Conditions

Interventions

DRUG

Leuprolide acetate

in experimentals groups,on fifth and tenth day after embryo transfer 0,5mg leuprolide acetate is given subcutaneously as luteal phase support

DRUG

vaginal progesterone

crinone gel is applied till fetal heart beat is detected

DRUG

4 mg oral estradiol valerate

estrofem is given twice a day

Sponsors & Collaborators

  • Zekai Tahir Burak Women's Health Research and Education Hospital

    lead OTHER

Principal Investigators

  • Nagihan Cengaver, Resident · Zekai Tahir Burak Women's Health Research and Education Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
38 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2015-02-28
Completion
2015-04-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02114645 on ClinicalTrials.gov